Cambium Bio (Australia) Performance
| CMB Stock | 0.51 0.02 3.77% |
Cambium Bio has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.72, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cambium Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Cambium Bio is expected to be smaller as well. Cambium Bio right now shows a risk of 2.27%. Please confirm Cambium Bio jensen alpha, sortino ratio, and the relationship between the standard deviation and total risk alpha , to decide if Cambium Bio will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cambium Bio are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental drivers, Cambium Bio may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
Last Split Factor 1:100 | Last Split Date 2024-07-04 |
1 | Cambium Bio Limited Issues New Shares - TipRanks | 10/15/2025 |
2 | ASX Stock Market News Australian Shares - new.smallcaps.com.au | 10/30/2025 |
| Begin Period Cash Flow | 2.9 M |
Cambium |
Cambium Bio Relative Risk vs. Return Landscape
If you would invest 48.00 in Cambium Bio on September 3, 2025 and sell it today you would earn a total of 3.00 from holding Cambium Bio or generate 6.25% return on investment over 90 days. Cambium Bio is generating 0.1214% of daily returns assuming 2.272% volatility of returns over the 90 days investment horizon. Simply put, 20% of all stocks have less volatile historical return distribution than Cambium Bio, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cambium Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cambium Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cambium Bio, and traders can use it to determine the average amount a Cambium Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0534
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | CMB | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.27 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Cambium Bio is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cambium Bio by adding it to a well-diversified portfolio.
Cambium Bio Fundamentals Growth
Cambium Stock prices reflect investors' perceptions of the future prospects and financial health of Cambium Bio, and Cambium Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cambium Stock performance.
| Return On Equity | -3.55 | ||||
| Return On Asset | -0.63 | ||||
| Current Valuation | 11.92 M | ||||
| Shares Outstanding | 22.97 M | ||||
| Price To Book | 6.32 X | ||||
| Price To Sales | 1,914 X | ||||
| Revenue | 988.43 K | ||||
| Gross Profit | 1.02 M | ||||
| EBITDA | (724.6 K) | ||||
| Net Income | (3.84 M) | ||||
| Total Debt | 317 K | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (660.46 K) | ||||
| Earnings Per Share | (0.21) X | ||||
| Total Asset | 3.3 M | ||||
| Retained Earnings | (46.59 M) | ||||
About Cambium Bio Performance
Assessing Cambium Bio's fundamental ratios provides investors with valuable insights into Cambium Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cambium Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cambium Bio is entity of Australia. It is traded as Stock on AU exchange.Things to note about Cambium Bio performance evaluation
Checking the ongoing alerts about Cambium Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cambium Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cambium Bio has some characteristics of a very speculative penny stock | |
| Cambium Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 988.43 K. Net Loss for the year was (3.84 M) with profit before overhead, payroll, taxes, and interest of 1.02 M. | |
| Cambium Bio generates negative cash flow from operations | |
| About 63.0% of the company shares are held by company insiders |
- Analyzing Cambium Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cambium Bio's stock is overvalued or undervalued compared to its peers.
- Examining Cambium Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cambium Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cambium Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cambium Bio's stock. These opinions can provide insight into Cambium Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cambium Stock Analysis
When running Cambium Bio's price analysis, check to measure Cambium Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cambium Bio is operating at the current time. Most of Cambium Bio's value examination focuses on studying past and present price action to predict the probability of Cambium Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cambium Bio's price. Additionally, you may evaluate how the addition of Cambium Bio to your portfolios can decrease your overall portfolio volatility.